Trials / Completed
CompletedNCT01337206
SX ELLA Esophageal Degradable BD Stent System
Evaluation of the Effectiveness of the SX ELLA Esophageal Degradable BD (BD Stent) Stent System
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- Cook Group Incorporated · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The SX-ELLA Stent Esophageal Degradable BD (BD Stent) is designed for dilation of benign esophageal lesions, namely: (1) stenosis (peptic, anastomotic or caustic) refractory to standard therapy, (2) achalasia refractory to standard therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Stenting with ELLA Biodegradable stent | Treating benign esophageal lesions with the placement of a degradable stent |
| PROCEDURE | Standard Dilations | Treating benign esophageal lesions with standard dilation therapy |
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2014-07-01
- Completion
- 2015-01-01
- First posted
- 2011-04-18
- Last updated
- 2015-02-06
Locations
8 sites across 5 countries: Belgium, Italy, Netherlands, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT01337206. Inclusion in this directory is not an endorsement.